Page last updated: 2024-08-24

imiquimod and vtx-2337

imiquimod has been researched along with vtx-2337 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dietsch, GN; Disis, ML; Ghanekar, S; Henderson, KE; Hershberg, RM; Howbert, JJ; Inokuma, M; Lu, H; Maino, VC; Matthews, MA; Suni, M; Yang, Y	1

Other Studies

1 other study(ies) available for imiquimod and vtx-2337

Article	Year
VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jan-15, Volume: 18, Issue:2 Topics: Aminoquinolines; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Benzazepines; Dendritic Cells; Drug Synergism; HEK293 Cells; Humans; Imiquimod; Inflammation Mediators; Interferon-gamma; Interleukin-12; Killer Cells, Natural; Leukocytes, Mononuclear; NF-kappa B; Oligodeoxyribonucleotides; Polymorphism, Single Nucleotide; Receptors, IgG; Rituximab; Toll-Like Receptor 8; Tumor Necrosis Factor-alpha	2012

Article

Year

VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jan-15, Volume: 18, Issue:2

Topics: Aminoquinolines; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Benzazepines; Dendritic Cells; Drug Synergism; HEK293 Cells; Humans; Imiquimod; Inflammation Mediators; Interferon-gamma; Interleukin-12; Killer Cells, Natural; Leukocytes, Mononuclear; NF-kappa B; Oligodeoxyribonucleotides; Polymorphism, Single Nucleotide; Receptors, IgG; Rituximab; Toll-Like Receptor 8; Tumor Necrosis Factor-alpha

2012